Novo Nordisk has a total of 1395 patents globally, out of which 642 have been granted. Of these 1395 patents, more than 49% patents are active. European Countries is where Novo Nordisk has filed the maximum number of patents, followed by USA and Japan, it has generated an annual revenue of $52.36 billion in the year 2021. Parallelly, USA seems to be the main focused R&D centre.
Novo Nordisk was founded in the year 1923 by August Krogh and Marie Krogh. Headquartered in Bagsvaerd, Denmark, it is a Danish multinational pharmaceutical corporation. It develops, manufactures, and distributes pharmaceutical products and services, with a focus on diabetes drugs and devices. As of April 2022, Novo Nordisk has a market cap of $268.69 Billion.
Do read about some of the most popular patents of Novo Nordisk which have been covered by us in this article and also you can find Novo Nordisk’ patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Novo Nordisk’ patent portfolio.
How many patents does the founder and the CEO of Novo Nordisk have?
The founders, August Krogh and Marie Krogh, have 7 and 0 patents respectively. The CEO, Lars Fruergaard Jørgensen, has 0 patents.
How Many Patents did Novo Nordisk File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Novo Nordisk Applications Filed | Novo Nordisk Patents Granted |
| 2011 | 68 | 29 |
| 2012 | 41 | 44 |
| 2013 | 45 | 42 |
| 2014 | 52 | 50 |
| 2015 | 48 | 31 |
| 2016 | 10 | 36 |
| 2017 | 38 | 44 |
| 2018 | 72 | 32 |
| 2019 | 76 | 38 |
| 2020 | 69 | 29 |
| 2021 | 56 | 44 |
| 2022 | – | 14 |
How many patents does Novo Nordisk have?
Novo Nordisk has a total of 1395 patents globally. These patents belong to 232 unique patent families. Out of 1395 patents, 696 patents are active.
How many Novo Nordisk patents are Alive/Dead?
Worldwide Patents
How Many Patents did Novo Nordisk File in Different Countries?
Countries in which Novo Nordisk Filed Patents
| Country | Patents |
| Europe | 140 |
| United States Of America | 121 |
| Japan | 110 |
| Australia | 100 |
| Canada | 85 |
| Germany | 75 |
| Hong Kong (S.A.R.) | 66 |
| China | 62 |
| Israel | 53 |
| Korea (South) | 49 |
| Spain | 48 |
| India | 41 |
| Brazil | 38 |
| Mexico | 37 |
| New Zealand | 36 |
| Singapore | 29 |
| South Africa | 21 |
| Austria | 21 |
| Denmark | 20 |
| Russia | 17 |
| Taiwan | 14 |
| Portugal | 13 |
| Chile | 10 |
| Poland | 9 |
| Indonesia | 6 |
| Hungary | 6 |
| Czech Republic | 5 |
| Norway | 5 |
| Argentina | 4 |
| Malaysia | 3 |
| Colombia | 2 |
| Viet Nam | 2 |
| Lithuania | 2 |
| Peru | 2 |
| Cyprus | 2 |
| Philippines | 1 |
| Slovakia | 1 |
| Finland | 1 |
| Macao | 1 |
| Slovenia | 1 |
| Dominican Republic | 1 |
| Costa Rica | 1 |
| Ecuador | 1 |
| Croatia | 1 |
| Uruguay | 1 |
| Albania | 1 |
| Morocco | 1 |
| Serbia | 1 |
| Jordan | 1 |
Which Novo Nordisk Drug Patents are Expiring in the Next 10 Years?
The patent no. US9968659B2 which is expiring in Jan, 2037, describing use of liraglutide to treat type 2 diabetes in individuals with vascular diseases or risk factors. Administering a therapeutically effective amount to those with cardiovascular, cerebrovascular, or peripheral vascular diseases, chronic renal failure, chronic heart failure, and/or risk factors like microalbuminuria, proteinuria, hypertension, and others..
Given below is the list of few drugs patented by Novo Nordisk accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Saxenda | US9968659B2 | Liraglutide In Cardiovascular Conditions | Jan, 2037 |
| Ozempic | US8129343B2 | Acylated GLP-1 Compounds | Dec, 2031 |
| Rybelsus | US10278923B2 | Oral Dosing Of GLP-1 Compounds | May, 2034 |
| Victoza | US9265893B2 | Injection Button | Sep, 2032 |
| Wegovy | US10888605B2 | GLP-1 Compositions And Uses Thereof | Aug, 2038 |
Interested in knowing about Novo Nordisk’s Drug Patents Expiring in the next 10 years?
Where are Research Centres of Novo Nordisk Patents Located?
10 Best Novo Nordisk Patents
US8513207B2 is the most popular patent in the Novo Nordisk portfolio. It has received 173 citations so far from companies like Genentech, Dicerna Pharmaceuticals, and Omega Therapeutics.
Below is the list of 10 most cited patents of Novo Nordisk:
| Publication Number | Citation Count |
| US8513207B2 | 173 |
| WO2013059496A1 | 155 |
| US8349809B2 | 135 |
| WO2002002509A1 | 120 |
| US20020065255A1 | 113 |
| WO2008028859A1 | 78 |
| WO2002016309A1 | 70 |
| WO2010033225A2 | 68 |
| US6610329B2 | 67 |
| WO2007121318A2 | 66 |
Which Companies are using Novo Nordisk Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Novo Nordisk patent portfolio are Arrowhead Pharmaceuticals, Roche Holding, and Novartis.
List of the top forward citing Companies –
| Company | Number of Patents |
| Arrowhead Pharmaceuticals | 10 |
| Roche Holding | 3 |
| Novartis | 3 |
| Translate Bio Ma | 3 |
| Keybioscience | 3 |
| Nanosur | 3 |
| Olix Pharmaceuticals | 2 |
| Alnylam Pharmaceuticals | 2 |
| Honeywell | 2 |
| Ionis Pharmaceuticals | 1 |
Count of 102 and 103 Type Rejections based on Novo Nordisk Patents
Top Novo Nordisk Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US20020065255A1 | 7 |
| US20030198666A1 | 6 |
| US20060078622A1 | 5 |
| US9458457B2 | 5 |
| US20100249214A1 | 5 |
| US8815825B2 | 4 |
| US20110288147A1 | 4 |
| US9701966B2 | 4 |
| US20120095200A1 | 4 |
| US20170305956A1 | 3 |
| US20050203001A1 | 3 |
| US8349809B2 | 3 |
| US20110059187A1 | 3 |
| US20120263738A1 | 3 |
| US8513207B2 | 2 |
Type 1 diabetes is a chronic illness in which the body’s capacity to convert glucose from food into energy is impaired. Type 1 diabetes usually develops early in life and is diagnosed during childhood. People with type 1 diabetes would not be able to sustain life if they did not receive daily insulin injections.
Their scientists are advancing research to reduce the number of insulin injections required to maintain good glycaemic control and to prevent low blood glucose (hypoglycaemic) episodes.
The natural GLP-1 hormone is also receiving a lot of interest from the pharmaceutical company. They’re learning more and more about the role that this naturally occurring hormone appears to play in weight loss success. GLP-1 molecules in the body, for example, impact a person’s hunger feelings after they’ve finished a meal.
They’ve been researching how synthetic GLP-1 molecules can be utilised to suppress appetite or raise energy expenditure for numerous years. They’ll also keep looking into how GLP-1 can promote long-term weight loss.
EXCLUSIVE INSIGHTS COMING SOON!
What are Novo Nordisk’s key innovation segments?